Table 2.

Recommended dose and treatment duration for adult and adolescent patients with different type of CIndU

Type of CIndU∗	Recommended dose	Recommended treatment duration
Symptomatic dermographism	300 mg/4 week	At least 12 months, then the dose and treatment duration should be adjusted according to clinical needs
Cold urticaria
Cholinergic urticaria

∗In clinical studies enrolled patients with CIndU, omalizumab is safe and has a similar incidence of adverse events as placebo. Omalizumab is indicated for symptomatic dermographism, cold urticaria, cholinergic urticaria in China and worldwide.50, 51, 52 Due to limited clinical evidence for delayed pressure urticaria, vibratory angioedema, heat urticaria, contact urticaria or aquagenic urticaria, it is recommended to consider according to the clinical situation. Recommended dose and treatment duration for patients younger than 12 years old with different type of CIndU refer to Table 1. CIndU: chronic inducible urticaria